Company intelligence / Profile preview

Blueback

Cambridge, Massachusetts, USAbluebackmovie.com ↗

Ownership: Private
Employees: ~50
Development stage: Other

Overview

BlueRock's lead program for Parkinson's disease has advanced to a registrational Phase III trial. The company published positive 18-month data from its Phase I trial for bemdaneprocel in Nature. OpCT‑001 received FDA Fast Track Designation and IND clearance for primary photoreceptor diseases.

Therapeutic areas: OphthalmologyNeurologyCardiovascular
Modalities: Cell therapyInduced pluripotent stem cell (iPSC)-derived cell therapy
Industry: Biotech

Partnerships

Bayer AGVersant VenturesMcEwen Center for Regenerative MedicineMemorial Sloan Kettering Cancer Center

Beyond the preview

Go deeper on Blueback.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Blueback.

Explore the full profile